Aileron Therapeutics Inc
NASDAQ:ALRN
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.65
6.931
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ALRN stock under the Base Case scenario is 0.81 USD. Compared to the current market price of 2.47 USD, Aileron Therapeutics Inc is Overvalued by 67%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Aileron Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ALRN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Aileron Therapeutics Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Aileron Therapeutics Inc
Balance Sheet Decomposition
Aileron Therapeutics Inc
Current Assets | 18.7m |
Cash & Short-Term Investments | 17.7m |
Other Current Assets | 1m |
Non-Current Assets | 85.5m |
PP&E | 1k |
Intangibles | 85.5m |
Other Non-Current Assets | 2k |
Current Liabilities | 5.7m |
Accounts Payable | 1.1m |
Accrued Liabilities | 4.6m |
Non-Current Liabilities | 3.3m |
Other Non-Current Liabilities | 3.3m |
Earnings Waterfall
Aileron Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-29.6m
USD
|
Operating Income
|
-29.6m
USD
|
Other Expenses
|
376k
USD
|
Net Income
|
-29.2m
USD
|
Free Cash Flow Analysis
Aileron Therapeutics Inc
USD | |
Free Cash Flow | USD |
ALRN Profitability Score
Profitability Due Diligence
Aileron Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Aileron Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
ALRN Solvency Score
Solvency Due Diligence
Aileron Therapeutics Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Aileron Therapeutics Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALRN Price Targets Summary
Aileron Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for ALRN is 13.26 USD with a low forecast of 7.07 USD and a high forecast of 19.95 USD.
Dividends
Current shareholder yield for ALRN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ALRN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aileron Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2017-06-29. The firm is focused on developing medicines to make chemotherapy safer. ALRN-6924, is its MDM2/MDMX dual inhibitor, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focuses on treating patients with p53-mutated cancers. The company is developing ALRN-6924 to selectively protect healthy cells in patients with p53-mutated cancers to reduce or eliminate chemotherapy-induced toxicities. The company stabilizes peptides by stapling them with hydrocarbon bonds into their natural alpha-helical conformation. Its platform enables it to chemically stabilize and improve the activity of a range of alpha-helical peptides. ALRN-6924 can pause cell division in cells with wild type (WT), p53, including normal bone marrow cells, and ALRN-6924 has no activity against cancer cells with mutations in p53.
Contact
IPO
Employees
Officers
The intrinsic value of one ALRN stock under the Base Case scenario is 0.81 USD.
Compared to the current market price of 2.47 USD, Aileron Therapeutics Inc is Overvalued by 67%.